We are live on ! Find out more
APLT

Applied Therapeutics

Delisted

APLT was delisted on the 2nd of February, 2026.

70 hedge funds and large institutions have $251M invested in Applied Therapeutics in 2021 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 21 increasing their positions, 18 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 18

14% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 7

1% more funds holding

Funds holding: 6970 (+1)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

1.21% less ownership

Funds ownership: 58.93%57.71% (-1.2%)

20% less call options, than puts

Call options by funds: $1.29M | Put options by funds: $1.62M

21% less capital invested

Capital invested by funds: $319M → $251M (-$68.2M)

Holders
70
Holders Change
+1
Holders Change %
+1.45%
% of All Funds
1.23%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
8
Increased
21
Reduced
18
Closed
7
Calls
$1.29M
Puts
$1.62M
Net Calls
-$322K
Net Calls Change
+$781K
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$40M -$166K -9,593 -0.4%
O
2
OrbiMed
New York
$37.5M
BlackRock
3
BlackRock
New York
$21.5M -$333K -19,285 -1%
KCM
4
Knoll Capital Management
Florida
$17.1M
Point72 Asset Management
5
Point72 Asset Management
Connecticut
$16.9M +$9.03M +522,771 +106%
Vanguard Group
6
Vanguard Group
Pennsylvania
$14.1M +$93.5K +5,417 +0.6%
Franklin Resources
7
Franklin Resources
California
$13.8M +$74.2K +4,300 +0.5%
RSCM
8
Rock Springs Capital Management
Maryland
$11.6M
DCM
9
Driehaus Capital Management
Illinois
$10.6M -$80K -4,633 -0.7%
Alkeon Capital Management
10
Alkeon Capital Management
New York
$10.6M -$6.94M -401,876 -39%
EMFAT
11
Emerald Mutual Fund Advisers Trust
Pennsylvania
$10.3M -$545K -31,539 -5%
EA
12
Emerald Advisers
Pennsylvania
$9.39M -$57.6K -3,335 -0.6%
AG
13
Artal Group
Luxembourg
$6.64M
Geode Capital Management
14
Geode Capital Management
Massachusetts
$5.25M +$435K +25,174 +9%
State Street
15
State Street
Massachusetts
$5.21M +$507K +29,382 +10%
Northern Trust
16
Northern Trust
Illinois
$2.96M -$204K -11,804 -6%
VOYA Investment Management
17
VOYA Investment Management
Georgia
$1.88M -$162K -9,408 -8%
N
18
Nuveen
North Carolina
$1.24M -$293K -16,993 -19%
First Manhattan
19
First Manhattan
New York
$1.22M
Bank of New York Mellon
20
Bank of New York Mellon
New York
$1.12M +$155K +8,955 +15%
Goldman Sachs
21
Goldman Sachs
New York
$1.03M +$43.9K +2,545 +4%
Russell Investments Group
22
Russell Investments Group
United Kingdom
$901K
Susquehanna International Group
23
Susquehanna International Group
Pennsylvania
$863K -$366K -21,182 -29%
Dimensional Fund Advisors
24
Dimensional Fund Advisors
Texas
$832K +$596K +34,521 +220%
Charles Schwab
25
Charles Schwab
California
$720K -$5.47K -317 -0.7%

APLT Hedge Fund Activity: Q3 2021 in Review

70 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Applied Therapeutics (APLT) for Q3 2021, worth a combined $251M — down 21% from $319M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new APLT positions and 7 closed out — a net gain of 1 holder — while 21 added to existing stakes and 18 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $9.03M. The largest seller was Alkeon Capital Management, cutting an estimated $6.94M.

  • 70 institutional investors held Applied Therapeutics (APLT) as of Q3 2021, up from 69 in Q2 2021.
  • Funds reported $251M of Applied Therapeutics stock for Q3 2021, down 21% quarter-over-quarter.
  • 8 funds opened new Applied Therapeutics positions in Q3 2021 and 7 closed out, a net change of +1 holder.
  • The largest Applied Therapeutics buyer in Q3 2021 was Point72 Asset Management, an estimated $9.03M added.
  • The largest Applied Therapeutics seller in Q3 2021 was Alkeon Capital Management, an estimated $6.94M sold.

Based on aggregated 13F filings for Q3 2021.